All News

Found 1,994 articles

• Elevar Therapeutics Names Brian Cunningham Vice President of Sales and Kenneth Rankin Vice President of Market Access, Strengthening Commercial Leadership in Buildup to Launch

  10/23/2023

  Elevar Therapeutics, Inc. today announced the hiring of Brian Cunningham as vice president of sales and Kenneth Rankin as vice president of market access.

• 

  Flagship’s Laronde, Senda Form Company Focused on New Class of Medicines

  10/20/2023

  Sail Biomedicines combines Laronde’s circular eRNA platform with Senda’s nanoparticle delivery technology in the pursuit of a new class of programmable medicines across therapeutic areas.

• Clinical Trials Market is Rising Rapidly Up to USD 95 BN by 2030

  10/18/2023

  As per Vision Research Reports, the global clinical trials market size is expected to surpass around USD 95 billion by 2030 from valued USD 51.78 billion in 2022, expanding growth at a CAGR of 7.07% during forecast period 2022 to 2030.

• Incyte to Present at Upcoming Investor Conferences - October 18, 2023

  10/18/2023

  Incyte (Nasdaq:INCY) announced today that it will present at the following investor conferences during the month of November.

• Incyte Announces New Data from across its Oncology Portfolio to be Presented at ESMO Congress 2023

  10/16/2023

  Incyte (Nasdaq:INCY) today announced that abstracts featuring new data from its oncology portfolio will be presented at the upcoming European Society for Medical Oncology (ESMO) Congress 2023, held October 20-24 in Madrid.

• Astex CSO David Rees Honoured as a Hero of Chemistry by the American Chemical Society

  10/13/2023

  The award recognises researchers and companies for developing products that have led to significant advancements in improving health and the environment.

• Incyte Announces New Data for Ruxolitinib Cream (Opzelura®) in Children with Atopic Dermatitis

  10/13/2023

  Incyte (Nasdaq:INCY) today announced expanded results from the pivotal Phase 3 TRuE-AD3 study evaluating the safety and efficacy of ruxolitinib cream (Opzelura®) in children (age ≥2 to <12 years) with atopic dermatitis (AD), the most common type of eczema.

• Data From Incyte’s Povorcitinib Clinical Program to Be Featured at the 8th Annual Symposium on Hidradenitis Suppurativa Advances (SHSA)

  10/13/2023

  Incyte (Nasdaq:INCY) today announced that multiple abstracts featuring new data from the company’s clinical program on povorcitinib, an investigational oral JAK-1 inhibitor, have been accepted for oral presentation at the 8th Annual Symposium on Hidradenitis Suppurativa Advances (SHSA) held October 13-15 in Phoenix.

• New Long-Term Data from Incyte Phase 3 TRuE-V Program Demonstrates Efficacy of Continued Treatment with Opzelura® (Ruxolitinib) Cream in Nonsegmental Vitiligo Patients

  10/11/2023

  Incyte (Nasdaq:INCY) today announced new results of a pooled analysis of long-term extension (LTE) data from the pivotal Phase 3 TRuE-V program assessing Opzelura® (ruxolitinib) cream 1.5% in patients 12 years of age and older with nonsegmental vitiligo who previously experienced limited or no response to treatment at Week 24.

• Incyte Announces Positive 52-Week Data from Phase 2b Study Evaluating Povorcitinib (INCB54707) in Patients with Extensive Nonsegmental Vitiligo

  10/11/2023

  Incyte (Nasdaq:INCY) today announced new 52-week data from a Phase 2b clinical trial evaluating the safety and efficacy of povorcitinib (INCB54707), an investigational oral JAK1 inhibitor, in adult patients with extensive nonsegmental vitiligo.

• Incyte to Report Third Quarter Financial Results - October 10, 2023

  10/10/2023

  Incyte (Nasdaq:INCY) announced today that it has scheduled its third quarter financial results conference call and webcast for 8:00 a.m. ET on Tuesday, October 31, 2023.

• Innovent and IASO Bio Present Updated Long-Term Follow-Up Data for BCMA CAR-T FUCASO® (Equecabtagene Autoleucel) at IMS 2023

  9/29/2023

  Innovent Biologics, Inc. and IASO Bio announced updated long-term follow-up data from two studies for BMCA CAR-T.

• Incyte to Present Multiple Studies from Dermatology Portfolio at 2023 European Academy of Dermatology and Venereology (EADV) Congress

  9/29/2023

  Incyte (Nasdaq:INCY) today announced multiple abstracts featuring new data from across its dermatology portfolio have been accepted for presentation at the upcoming European Academy of Dermatology and Venereology (EADV) Congress 2023 held October 11-14 in Berlin.

• IASO Bio Presents Updated Long-Term Follow-Up Data for BCMA CAR-T FUCASO® (Equecabtagene Autoleucel) at IMS 2023

  9/28/2023

  IASO Bio and Innovent Biologics, Inc. announced updated long-term follow-up data from two studies for BMCA CAR-T.

• Arcutis Appoints L. Todd Edwards as Chief Commercial Officer

  9/27/2023

  Arcutis Biotherapeutics, Inc. today announced the appointment of Todd Edwards as Chief Commercial Officer (CCO), effective immediately.

• AbCellera Announces Collaboration with Incyte to Accelerate the Discovery and Development of Therapeutic Antibodies in Oncology

  9/13/2023

  AbCellera (Nasdaq:ABCL) announced today that it has entered into a strategic collaboration with Incyte (Nasdaq:INCY) to discover and develop therapeutic antibodies in oncology.

• MorphoSys Receives U.S. FDA Fast Track Designation for Tulmimetostat in Endometrial Cancer

  9/12/2023

  MorphoSys AG (FSE:MOR)(NASDAQ:MOR) today announced that the U.S. Food and Drug Administration (FDA) granted Fast Track designation for tulmimetostat, the company's investigational next-generation dual inhibitor of EZH2 and EZH1, for the treatment of patients with advanced, recurrent or metastatic endometrial cancer harboring AT-rich interacting domain containing protein 1A (ARID1A) mutations and who have progressed on at least one prior line of treatment.

• BriaCell Reports Benchmark-Beating Patient Survival and Clinical Benefit in Advanced Metastatic Breast Cancer

  9/8/2023

  BriaCell Therapeutics Corp. today announces the completion of patient enrollment in its Phase 2 clinical study and reports clinical data showing strong patient survival benefit and clinical benefit in advanced metastatic breast cancer patients.

• Alpenglow Biosciences presents the 3D Spatial Summit, an inaugural event for the field of 3D Spatial Biology to take place on September 21, 2023 in Cambridge, Massachusetts

  8/29/2023

  Alpenglow Biosciences (Alpenglow), creators of an innovative end-to-end 3D spatial biology platform and suite of quantitative spatial statistical analysis tools, revealed their first annual 3D Spatial Summit scheduled for September 21, 2023 in Cambridge, Massachusetts.

• Medicenna Announces the Appointment of Jeff Caravella as Chief Financial Officer

  8/28/2023

  Medicenna Therapeutics Corp., a clinical-stage immunotherapy company, announced the appointment of Jeff Caravella as Chief Financial Officer.